Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): A case series
| Autor: | Jurr Boer, Lennart Emtestam, Karin Sartorius, Ditte Marie Saunte, Inge Evon Deckers, Peter Theut Riis, Gregor B.E. Jemec, Errol P. Prens |
|---|---|
| Přispěvatelé: | Dermatology |
| Rok vydání: | 2016 |
| Předmět: |
Adult
medicine.medical_specialty Triamcinolone acetonide Erythema medicine.drug_class Anti-Inflammatory Agents Pain Dermatology Injections Intralesional Triamcinolone Chronic inflammatory disease Severity of Illness Index 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Edema Severity of illness medicine Humans Hidradenitis suppurativa Prospective Studies Prospective cohort study Suppuration business.industry medicine.disease Hidradenitis Suppurativa Treatment Outcome 030220 oncology & carcinogenesis Corticosteroid medicine.symptom business medicine.drug |
| Zdroj: | Journal of the American Academy of Dermatology, 75(6), 1151-1155. Mosby Inc. |
| ISSN: | 0190-9622 |
| DOI: | 10.1016/j.jaad.2016.06.049 |
| Popis: | Hidradenitis suppurativa (HS) is a chronic inflammatory disease of the hair follicle. Standard practice of managing acute flares with corticosteroid injection lacks scientific evidence.We sought to assess the outcomes of routine treatment using intralesional triamcinolone (triamcinolone acetonide 10 mg/mL) in the management of acute flares in HS.This was a prospective case series evaluating the effect of intralesional corticosteroids for alleviation of acute flares in HS. Physician- and patient-reported outcomes were noted.Significant reductions in physician-assessed erythema (median score from 2-1, P .0001), edema (median score from 2-1, P .0001), suppuration (median score from 2-1, P .0001), and size (median score from 3-1, P .0001) was demonstrated at follow-up. A significant difference in patient-reported pain visual analog scale scores occurred after 1 day (from 5.5-2.3, P .005) and from day 1 to day 2 (from 2.3-1.4, P .002).Small study size, open single-arm design, and short follow-up time are the limitations of this study.Intralesional injection of corticosteroids is perceived as beneficial by physicians and patients in the management of HS flares by reducing pain after 1 day and signs of inflammation approximately 7 days later. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect